Evidence map›Paper›PMID 38528050›Full record

ArticleSignal transduction and targeted therapy2024

First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.

Xiaofeng Chen, Hao Xu, Xiaobing Chen, Tongpeng Xu, Yitong Tian, Deqiang Wang, Fen Guo, Kangxin Wang, Guangfu Jin, Xiao Li and 18 more

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Advancements in targeted therapy for gastric cancer.Therapeutic advances in gastroenterology · 2026
    Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 7 institutions in 1 country.

Xiaofeng Chen *Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Hao Xu *Department of General surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xiaobing Chen *Department of Oncology, Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Tongpeng Xu *Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yitong TianDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Deqiang WangDepartment of Oncology, Digestive Disease Institute & Cancer Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Fen GuoDepartment of Oncology, Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Kangxin WangDepartment of Oncology, Nanjing PuKou People's Hospital, Nanjing, China.
Guangfu JinDepartment of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
Xiao LiDepartment of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Rong WangDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Fengyuan LiDepartment of General surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yongbin DingDepartment of general surgery, Jurong Branch hospital of Jiangsu Province People Hospital, Jurong, China.
Jie TangDepartment of Medical Oncology, Liyang People's Hospital, Liyang, China.
Yueyu FangDepartment of Oncology, Nanjing PuKou People's Hospital, Nanjing, China.
Jing ZhaoDepartment of Oncology, Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Liang LiuDepartment of radiology, Nanjing PuKou People's Hospital, Nanjing, China.
Ling MaDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Lijuan MengDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Zhiguo HouJiangsu Hengrui Pharmaceuticals, Shanghai, China.
Rongrong ZhengJiangsu Hengrui Pharmaceuticals, Shanghai, China.
Yang LiuJiangsu Hengrui Pharmaceuticals, Shanghai, China.
Ni GuanJiangsu Hengrui Pharmaceuticals, Shanghai, China.
Bei ZhangDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, China.
Shuang TongDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, China.
Shiqing ChenDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, China.
Xing LiShanghai OrigiMed Co., Ltd., Shanghai, China.
Yongqian ShuDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. shuyongqian@csco.org.cn.
Nanjing Medical University · CNJiangsu Hengrui Medicine (China) · CNHenan Cancer Hospital · CNGuiyang Medical University · CNJiangsu Province Hospital · CNJiangsu University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with advanced gastric cancer typically face a grim prognosis. This phase 1a (dose escalation) and phase 1b (dose expansion) study investigated safety and efficacy of first-line camrelizumab plus apatinib and chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma. The primary endpoints included maximum tolerated dose (MTD) in phase 1a and objective response rate (ORR) across phase 1a and 1b. Phase 1a tested three dose regimens of camrelizumab, apatinib, oxaliplatin, and S-1. Dose regimen 1: camrelizumab 200 mg on day 1, apatinib 250 mg every other day, oxaliplatin 100 mg/m² on day 1, and S-1 40 mg twice a day on days 1-14. Dose regimen 2: same as dose regimen 1, but oxaliplatin 130 mg/m². Dose regimen 3: same as dose regimen 2, but apatinib 250 mg daily. Thirty-four patients were included (9 in phase 1a, 25 in phase 1b). No dose-limiting toxicities occurred so no MTD was identified. Dose 3 was set for the recommended phase 2 doses and administered in phase 1b. The confirmed ORR was 76.5% (95% CI 58.8-89.3). The median progression-free survival was 8.4 months (95% CI 5.9-not evaluable [NE]), and the median overall survival (OS) was not mature (11.6-NE). Ten patients underwent surgery after treatment and the multidisciplinary team evaluation. Among 24 patients without surgery, the median OS was 19.6 months (7.8-NE). Eighteen patients (52.9%) developed grade ≥ 3 treatment-emergent adverse events. Camrelizumab plus apatinib and chemotherapy showed favorable clinical outcomes and manageable safety for untreated advanced gastric cancer (ChiCTR2000034109).

Indexed as

Antibodies, Monoclonal, HumanizedPyridinesStomach NeoplasmsDrug Therapy, CombinationHumansImmune Checkpoint InhibitorsOxaliplatinVascular Endothelial Growth Factor Receptor-2Antibodies, Monoclonal, HumanizedapatinibcamrelizumabImmune Checkpoint InhibitorsOxaliplatinPyridinesVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID38528050
PMCPMC10963362
OpenAlexW4393152790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.